Benefits of Combining Cervical Cancer Screening with Human Papillomavirus Testing and Cytology
- VernacularTitle:子宮頸がん検診におけるHPV併用検診の有用性
- Author:
Akihiro KARUBE
1
;
Fumiko SAITO
1
;
Akihiro SHITARA
1
;
Enami NAKAMURA
1
;
Katsuhiro KANAMORI
1
;
Mizuki TAKAHASHI
1
;
Kozue IKEDA
2
;
Yuka KAWANA
3
Author Information
- From:Journal of the Japanese Association of Rural Medicine 2019;68(1):18-25
- CountryJapan
- Language:Japanese
- Abstract: This study sought to demonstrate the benefits of conducting cervical cytology and human papillomavirus (HPV) testing in our cervical cancer screening program and was conducted between April 2012 and March 2017 in the Yuri-Honjo district of Akita Prefecture. A total of 3581 women aged 20-49 years underwent this combined screening for 5 years. Of these, 10.3% (369/3581) tested positive for HPV, and 433 women were initially diagnosed as positive for atypical squamous cells of undetermined significance and/or positive for HPV. Of those, 342 women (79.0%) underwent cervical biopsy, among whom 62 (18.1%) were diagnosed as positive for cervical intraepithelial neoplasia (CIN)2+. Of 204 women who were positive for HPV but showed no abnormalities in cytology, 24 women (11.8%) were positive for CIN2+ and 6 women were positive for CIN3+. Conventional cytology (Pap test) detected only 0.58% of the examinees positive for CIN2+ in Akita Prefecture, whereas our combined screening involving a Pap test and HPV testing detected 1.73% of the examinees (P<0.0001). We recommend HPV testing be used in combination with the Pap test to improve cervical cancer screening and accurately identify CIN2/3 disease.
